Abstract
Background The Single combination budesonide-formoterol inhaler Maintenance And Reliever Therapy (SMART) regimen reduces severe asthma exacerbations in patients, but whether the high doses of corticosteroid and beta agonist increase the risk of adverse effects with both short-term and cumulative exposure is not certain. Our aim was to investigate whether the SMART regimen would reduce the risk of overuse of 13 agonist, reduce the likelihood of patients to seek medical review when such episodes occurred, and if any reduction in severe asthma exacerbations would be at the cost of a higher burden of systemic corticosteroid.
Methods In this 24-week trial undertaken at four primary health-care practices and one hospital in New Zealand, patients (aged 16-65 years) with a recent asthma exacerbation were randomly assigned in a 1:1 ratio to the SMART or standard fixed-dose regimen. Treatment in the SMART group consisted of two actuations of budesonide-formoterol (200 mu g and 6 mu g, respectively, per actuation) twice daily, delivered through a combination metered dose inhaler (MDI), with one extra actuation as needed for relief of symptoms; treatment in the standard group consisted of two actuations of budesonide-formoterol (200 mu g and 6 mu g, respectively, per actuation) twice daily through a combination MDI with one to two actuations of salbutamol (100 mu g per actuation) by MDI as needed for relief of symptoms. MDIs were monitored electronically to measure actual use of medication. The allocation sequence for randomisation was computer generated, with a block size of eight per site. Participants, investigators, and the statistician were not masked to group assignment. The primary outcome was the proportion of participants with at least one high-use episode of beta agonist (more than eight actuations per day of budesonide-formoterol in addition to the four maintenance doses in the SMART group or more than 16 actuations per day of salbutamol in the standard group). Analysis was by intention to treat. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12610000515099.
Findings 303 patients were randomly assigned to the SMART (n=151) or standard group (n=152). No significant difference was noted between the SMART and standard groups in the proportion of participants with at least one high-use episode of beta agonist (84 [56%] vs 68 [45%], respectively, relative risk 1.24 [95% CI 0-99-1.56]; p=0.058). There were fewer days of high use in the SMART group (mean 5.1 days [SD 14.3] vs 8.9 days [20.9], relative rate 0.58 [0.39-0.88]; p=0.01). Of the patients who had at least one high-use episode, those in the SMART group had fewer days of high use without medical review (8.5 days [17.8] vs 18.3 days [24.8], 0.49 [0.31-0.75]; p=0.001). The SMART regimen resulted in higher inhaled corticosteroid exposure (943.5 mu g budesonide per day [1502.5] vs 684.3 mu g budesonide per day [390.5], respectively; ratio of means 1.22 [1.06-1.41]; p=0.006), but reduced oral corticosteroid exposure (77.5 mg prednisone [240.5] vs 126.6 mg prednisone [382.1], respectively; p=0.011), with no significant difference in composite systemic corticosteroid exposure (793.7 mg prednisone equivalent per year [893.1] vs 772.1 mg prednisone equivalent per year [1062.7], respectively; 1.03 [0.86-1.22]; p=0.76). Participants in the SMART group had fewer severe asthma exacerbations (35 [weighted mean rate per year 0.53] vs 66 [0.97]; relative rate 0.54 [0.36-0.82]; p=0.004).
Interpretation The SMART regimen has a favourable risk-to-benefit profile and can be recommended for use in adults at risk of severe asthma exacerbations.